论文部分内容阅读
目的探讨缬沙坦治疗老年肥胖高血压患者的临床疗效。方法选取2013年2月—2014年2月某院收治的老年肥胖高血压患者91例,随机分为治疗组46例与对照组45例。对照组患者予以氨氯地平治疗,治疗组患者予以缬沙坦治疗。观察两组患者治疗前后24h血压〔24h收缩压(SBP)、24h舒张压(DBP)〕、心功能指标〔舒张期室间隔厚度(IVST)、左室舒张末内径(LVDd)、舒张期左心室后壁厚度(LVPWT)、左室重量指数(LVMI)〕、肾功能指标〔24h尿微量清蛋白(UAE)、血清肌酐(Scr)、血清尿素氮(BUN)〕、临床疗效及不良反应发生情况。结果治疗前后两组患者24h SBP、24h DBP比较,差异无统计学意义(P>0.05),两组患者治疗后24h SBP、24h DBP低于治疗前,差异有统计学意义(P<0.05);治疗前两组患者IVST、LVDd、LVPWT、LVMI比较,差异无统计学意义(P>0.05),治疗后治疗组患者IVST、LVDd、LVPWT、LVMI低于对照组,差异有统计学意义(P<0.05);治疗前两组患者UAE、Scr、BUN比较,差异无统计学意义(P>0.05);治疗后治疗组患者UAE低于对照组,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论缬沙坦治疗老年肥胖高血压患者的临床疗效显著,可降低患者血压,改善患者心功能和肾功能,且不良反应少。
Objective To investigate the clinical efficacy of valsartan in the treatment of elderly obese hypertensive patients. Methods Ninety-one elderly hypertensive patients admitted to our hospital from February 2013 to February 2014 were randomly divided into treatment group (n = 46) and control group (n = 45). Patients in the control group were treated with amlodipine, and patients in the treatment group were treated with valsartan. Blood pressure (24h systolic pressure (SBP) and 24h diastolic blood pressure (DBP)), heart function index (IVST, LVDd, diastolic left ventricle LVPWT, LVMI), renal function indexes (UAE, Scr, BUN), clinical efficacy and incidence of adverse reactions . Results There was no significant difference in 24h SBP and 24h DBP between the two groups before and after treatment (P> 0.05). There was significant difference in DBP and 24h DBP before and after treatment between the two groups (P <0.05). There were no significant differences in IVST, LVDd, LVPWT and LVMI between the two groups before treatment (P> 0.05). After treatment, the IVST, LVDd, LVPWT and LVMI in the treatment group were lower than those in the control group (P < 0.05). There was no significant difference in the UAE, Scr and BUN between the two groups before treatment (P> 0.05). After treatment, the UAE in the treatment group was lower than that in the control group (P <0.05) The incidence of adverse reactions in patients, the difference was not statistically significant (P> 0.05). Conclusion The clinical efficacy of valsartan in the treatment of elderly obese hypertensive patients is significant, which can reduce the patient’s blood pressure, improve the cardiac function and renal function, with less adverse reactions.